Second- and third-generation ALK inhibitors for non-small cell lung cancer

Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hematology and oncology 2016-03, Vol.9 (19), p.19-19, Article 19
Hauptverfasser:	Wu, Jingjing, Savooji, John, Liu, Delong
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Cancer Carbazoles - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - pathology Care and treatment Chemotherapy Complications and side effects Genetic aspects Health aspects Humans Kaplan-Meier Estimate Lactams, Macrocyclic - therapeutic use Lung cancer, Non-small cell Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - pathology Organophosphorus Compounds - therapeutic use Piperidines - therapeutic use Protein Kinase Inhibitors - therapeutic use Pyrimidines - therapeutic use Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Receptor Protein-Tyrosine Kinases - genetics Receptor Protein-Tyrosine Kinases - metabolism Review Sulfones - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.
ISSN:	1756-8722 1756-8722
DOI:	10.1186/s13045-016-0251-8